COMMUNIQUÉS West-GlobeNewswire

AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
01/07/2026
COMMUNIQUE DE PRESSE RESULTATS DE L’ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2026 Paris, 1 er juillet 2026, 10h Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le mardi 30 juin 2026 à [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management Follows recent $165m equity raise strengthening cash position Including equity financing and undrawn loan facility [...]
Urteste S.A. Receives U.S. Patent for the Panuri Test
01/07/2026
Urteste S.A. Receives U.S. Patent for the Panuri Test Gdansk, Poland – 01 July 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine [...]
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter [...]
Eurobio Scientific finalise l'acquisition de la division « Lab Products » de CareDX dédiée à la transplantation
01/07/2026
EUROBIO SCIENTIFIC FINALISE L'ACQUISITION DE LA DIVISION « LAB PRODUCTS 1 » DE CAREDX DÉDIÉE À LA TRANSPLANTATION Accélération du plan stratégique d’Eurobio visant à devenir un leader du diagnostic moléculaire in vitro [...]
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01/07/2026
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III [...]
Idorsia appoints Roland Wandeler as Chief Executive Officer
01/07/2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to [...]
Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology
01/07/2026
Professor Isidro Cortés-Ciriano, a n internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate discoveries into new therapies [...]
Eurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
01/07/2026
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading [...]
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
01/07/2026
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from [...]
Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026
Communiqué de presse Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé La demande d’autorisation de mise sur le [...]
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a [...]
Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK
01/07/2026
Acquisition centrée sur le potravitug, un anticorps monoclonal premier de sa classe au stade clinique, ciblant le polyomavirus BK L’ensemble des données issues de l’essai de phase II SAFE KIDNEY II soutient le lancement [...]
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 07h30 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société [...]
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
01/07/2026
Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug [...]
AB Science announces the successful completion of a EUR 2.3 million private placement
01/07/2026
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1 st , 2026, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) [...]
Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »
01/07/2026
Mise en ligne du document «Q2 2026 aide-mémoire » Paris, France – 1 juillet 2026 . Sanofi annonce la mise en ligne de son « Q2 2026 aide-mémoire » sur la page « Investisseurs » de sanofi.com. Résultats du second [...]
AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
01/07/2026
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE DE 2,3 MILLIONS D’EUROS Paris, 1 er juillet 2026, 8h AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce [...]

Pages